Literature DB >> 6295596

Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin.

W M Melia, P J Johnson, R Williams.   

Abstract

Following a pilot study of VP-16.213 (180 mg/m2 on 3 consecutive days at 2 weekly intervals) in the treatment of patients with hepatocellular carcinoma, the efficacy of the drug was compared with that of adriamycin in another 35 patients in a randomized crossover trial. Each drug gave a similar response rate (18 and 28%, respectively) but the duration of response was significantly longer in those receiving Adriamycin. Some patients who had not responded to treatment with Adriamycin had worthwhile remission with VP 16.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6295596     DOI： 10.1002/1097-0142(19830115)51:2<206::aid-cncr2820510206>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.

Authors:  Dae Won Kim; Chetasi Talati; Richard Kim
Journal:  J Gastrointest Oncol       Date:  2017-04

2.  Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE).

Authors:  H Yodono; S D Takekawa; K Tarusawa; I Ikami; J Kanehira; Y Saito; S Takahashi; T Sasaki; N Nishi; T Kimura
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Systemic therapy in hepatocellular carcinoma.

Authors:  Stephen H Wrzesinski; Tamar H Taddei; Mario Strazzabosco
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

4.  Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.

Authors:  Minaxi Jhawer; Lee Rosen; Janet Dancey; Howard Hochster; Solomon Hamburg; Margaret Tempero; Neil Clendeninn; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-09-07       Impact factor: 3.850

5.  Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma.

Authors: 
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies.

Authors:  H Yodono; T Sasaki; K Tarusawa; H Midorikawa; Y Saito; S D Takekawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Primary liver cancer in Hong Kong.

Authors:  W C Shiu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.

Authors:  Jeng-Nian Yuan; Yee Chao; Wei-Ping Lee; Chung-Pin Li; Rheun-Chuan Lee; Full-Young Chang; Sang-Hue Yen; Shou-Dong Lee; Jacqueline Whang-Peng
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

9.  Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study.

Authors:  Toru Ishikawa; Michitaka Imai; Hiroteru Kamimura; Atsunori Tsuchiya; Tadayuki Togashi; Kouji Watanabe; Kei-ichi Seki; Hironobu Ohta; Toshiaki Yoshida; Tomoteru Kamimura
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

10.  Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer.

Authors:  Y Sakata; Y Komatsu; S Takagi; S Saitoh; T Itoh; H Suzuki; K Tsushima; D Sasaki; Y Yoshida
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.